Axcella Health Inc(AXLA)Finding the best opportunities to buy and sell stocks daily.
Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The firm focuses on research and development of multifactorial interventions to support health and address dysregulated metabolism across a spectrum of consumers. The company designs and develops endogenous metabolic modulators. Its AXA Development Platform produces a pipeline of AXA candidates with programs in liver, muscle and blood. The Company’s wholly owned pipeline comprises five programs focused on the metabolic functions of the liver, muscle and blood. The company offers AXA1665 for use in treating Hepatic Encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways.
All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.